Trung Huynh
Stock Analyst at UBS
(4.82)
# 82
Out of 5,090 analysts
56
Total ratings
72.97%
Success rate
32.12%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Trung Huynh
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| REGN Regeneron Pharmaceuticals | Maintains: Neutral | $595 → $660 | $718.36 | -8.12% | 5 | Nov 7, 2025 | |
| LLY Eli Lilly and Company | Maintains: Buy | $895 → $1,080 | $1,010.31 | +6.90% | 10 | Nov 7, 2025 | |
| INSM Insmed | Maintains: Buy | $194 → $223 | $204.00 | +9.31% | 9 | Oct 31, 2025 | |
| JSPR Jasper Therapeutics | Maintains: Buy | $29 → $25 | $1.71 | +1,361.99% | 3 | Aug 15, 2025 | |
| AMGN Amgen | Maintains: Neutral | $326 → $317 | $329.89 | -3.91% | 6 | Aug 6, 2025 | |
| CLDX Celldex Therapeutics | Maintains: Buy | $44 → $38 | $29.45 | +29.03% | 2 | May 9, 2025 | |
| PFE Pfizer | Maintains: Neutral | $24 → $25 | $26.03 | -3.96% | 6 | Apr 30, 2025 | |
| BMY Bristol-Myers Squibb Company | Maintains: Neutral | $60 → $54 | $52.15 | +3.55% | 5 | Apr 11, 2025 | |
| CABA Cabaletta Bio | Maintains: Buy | $10 → $7 | $2.55 | +174.51% | 2 | Apr 1, 2025 | |
| KYTX Kyverna Therapeutics | Initiates: Buy | $13 | $7.80 | +66.67% | 1 | Oct 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $170 → $175 | $201.93 | -13.34% | 2 | Jul 21, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $125 → $126 | $99.72 | +26.35% | 3 | Mar 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $170 | $226.08 | -24.81% | 1 | Nov 18, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | n/a | $8.85 | - | 1 | Mar 23, 2021 |
Regeneron Pharmaceuticals
Nov 7, 2025
Maintains: Neutral
Price Target: $595 → $660
Current: $718.36
Upside: -8.12%
Eli Lilly and Company
Nov 7, 2025
Maintains: Buy
Price Target: $895 → $1,080
Current: $1,010.31
Upside: +6.90%
Insmed
Oct 31, 2025
Maintains: Buy
Price Target: $194 → $223
Current: $204.00
Upside: +9.31%
Jasper Therapeutics
Aug 15, 2025
Maintains: Buy
Price Target: $29 → $25
Current: $1.71
Upside: +1,361.99%
Amgen
Aug 6, 2025
Maintains: Neutral
Price Target: $326 → $317
Current: $329.89
Upside: -3.91%
Celldex Therapeutics
May 9, 2025
Maintains: Buy
Price Target: $44 → $38
Current: $29.45
Upside: +29.03%
Pfizer
Apr 30, 2025
Maintains: Neutral
Price Target: $24 → $25
Current: $26.03
Upside: -3.96%
Bristol-Myers Squibb Company
Apr 11, 2025
Maintains: Neutral
Price Target: $60 → $54
Current: $52.15
Upside: +3.55%
Cabaletta Bio
Apr 1, 2025
Maintains: Buy
Price Target: $10 → $7
Current: $2.55
Upside: +174.51%
Kyverna Therapeutics
Oct 10, 2024
Initiates: Buy
Price Target: $13
Current: $7.80
Upside: +66.67%
Jul 21, 2023
Maintains: Neutral
Price Target: $170 → $175
Current: $201.93
Upside: -13.34%
Mar 7, 2023
Maintains: Outperform
Price Target: $125 → $126
Current: $99.72
Upside: +26.35%
Nov 18, 2022
Initiates: Outperform
Price Target: $170
Current: $226.08
Upside: -24.81%
Mar 23, 2021
Upgrades: Outperform
Price Target: n/a
Current: $8.85
Upside: -